Evonik and AMSilk extend partnership for sustainable biotech silk materials

/in

Dedicated manufacturing line for AMSilk high-performance silk proteins High tech industrial biomaterials meet leading apparel brands’ demand for scalable, sustainable, alternatives Expanding Evonik’s portfolio of precision biosolutions ESSEN, Germany and NEURIED, Germany, Sept. 25, 2025 –  Evonik and AMSilk, a global leader in advanced biomaterials based on silk proteins, have deepened their collaboration with a long-term agreement to produce […]

Read more

Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

/in

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor Amsterdam, The Netherlands and Seongnam-Si, Korea, 25 September 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly […]

Read more

Poolbeg Pharma plc – ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost

/in

Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres  25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to […]

Read more

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

/in

At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2 ( p<0.0001) Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a Biologic License Application (BLA) under accelerated approval pathway […]

Read more
xeltis

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

/in

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency rates, with major improvements demonstrated across the board compared to standard of care Enhances clinical profile of aXess, reinforcing excellent first-in-human outcomes amid ongoing US pivotal trial and ahead of commercialization EINDHOVEN, The Netherlands, 24 […]

Read more
© Optimum Strategic Communications.